Research programme: H5N1 avian influenza vaccine - Takeda/University of Wisconsin

Drug Profile

Research programme: H5N1 avian influenza vaccine - Takeda/University of Wisconsin

Latest Information Update: 23 Jul 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator InViragen LLC; University of Wisconsin-Madison
  • Developer Takeda Pharmaceuticals USA; University of Wisconsin-Madison
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Influenza A virus H5N1 subtype

Most Recent Events

  • 23 Jul 2014 No development reported - Preclinical for Influenza-A virus H5N1 subtype in USA (Intranasal)
  • 31 May 2013 Inviragen has been acquired by Takeda Pharmaceuticals USA
  • 27 Jan 2011 Preclinical development is ongoing in USA for Influenza-A virus H5N1 subtype
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top